New strategies in lung cancer: Epigenetic therapy for non-small cell lung cancer

Research output: Contribution to journalArticle


Recent discoveries that non-small cell lung cancer (NSCLC) can be divided into molecular subtypes based on the presence or absence of driver mutations have revolutionized the treatment of many patients with advanced disease. However, despite these advances, a majority of patients are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and prolonged survival. In this article, we review the current status of attempts to target the epigenome, heritable modifications of DNA, histones, and chromatin that may act to modulate gene expression independently of DNA coding alterations, in NSCLC and the potential for combinatorial and sequential treatment strategies.

Original languageEnglish (US)
Pages (from-to)2244-2248
Number of pages5
JournalClinical Cancer Research
Issue number9
StatePublished - May 1 2014


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this